Here is their press release
Latham & Watkins is pleased to announce that Eveline Van Keymeulen has joined the firm as a partner in the Healthcare & Life Sciences Practice based in Paris and Brussels. Van Keymeulen advises multinational companies and start-ups in the pharmaceutical, biotech, medical devices, cosmetics, and food sectors on a broad variety of complex European, domestic and cross-border regulatory matters, including clinical trials, product approvals, regulatory incentives, market access, promotion and advertising, post-market obligations, and general compliance matters.
A rising star in her field, Van Keymeulen brings significant expertise advising at EU and national law levels, and she regularly counsels clients on key strategic legal and policy developments relating to the EU regulatory framework. She also has extensive experience advising on cannabis and hemp based product regulations.
“The healthcare and life sciences industry is a key strategic priority for the firm,” said John Manthei, Global Chair of Latham’s Healthcare & Life Sciences Practice. “As a highly regulated global sector, clients increasingly require advisors with command of the complex legal systems governing development, manufacturing, approval and commercialization of a wide range of life sciences products in multiple jurisdictions. Eveline’s deep knowledge and unique experience operating in the US and across the EU and a number of key European markets, including before the EU authorities and jurisdictions, will add further prominence to our global practice.”
“We are delighted to welcome Eveline to the firm”, said Olivia Rauch-Ravisé, Office Managing Partner of Latham & Watkins in Paris. “She is a highly skilled lawyer, with a fantastic reputation for handling complex regulatory matters. She brings a wealth of experience across a range of transactional and stand-alone regulatory work, and her arrival will help us achieve our strategic goal of developing the leading Healthcare & Life Sciences Practice in Europe as a major part of our global platform.”
“Latham has established an unmatched global life sciences practice, with top tier regulatory, IP, licensing, litigation, M&A, and capital markets expertise across the US, Europe, Asia, and the Middle East,” added Robbie McLaren, a London partner who serves as the Vice Chair of Latham’s global industry group focused on healthcare & life sciences. “The firm has a unique ability to support both global pharmaceutical as well as innovative biotechnology companies in transactional, litigation, and counselling matters in each major market across the world. Eveline’s industry relationships and extraordinarily deep product knowledge are highly complementary to the firm’s practice, and we are excited to welcome her to the team.”
Van Keymeulen joins the firm from Allen & Overy. She graduated with a degree in Law from Ghent University, and holds a Masters in European Law from Ghent University and an LLM from the University of California Berkeley School of Law, as well as a Masters in Intellectual Property Law from Brussels University. She is admitted to the Brussels, New York, and Paris bars.